Bruton Tyrosine Kinase as Therapeutic Target in Cardiovascular Diseases—Executive Summary
Thrombosis and Haemostasis · 08.07.2026
DOI: 10.1055/a-2886-8670 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 08.07.2026. Verfasst von Philipp von Hundelshausen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ludwig Maximillians University Munich, Institute for Cardiovascular Prevention, Bavaria, Germany, Munchen. Gefördert von: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation).
Abstract (Originalsprache)
Bruton tyrosine kinase (Btk) is an intracellular enzyme belonging to the Tec family tyrosine kinases. Initially identified for its role in B cell signaling, it has now emerged as a pivotal mediator in thrombosis and cardiovascular diseases (CVD). Beyond its established role in B cell malignancies, Btk is expressed in platelets, macrophages, neutrophils, and other innate immune cells, orchestrating platelet activation, atherothrombosis, venous thrombosis, immunothrombosis/thrombo-inflammation, and vascular inflammation. Patients with X-linked agammaglobulinemia (XLA), genetically lacking Btk, do not bleed, indicating that selective platelet Btk inhibition may provide a safe antithrombotic strategy. Indeed, highly selective Btk inhibitors (BTKi) show no or only minor bleeding in autoimmune disease trials, and rilzabrutinib, approved in 2025, reduces bleeding in patients with immune thrombocytopenia (ITP). This executive summary of a recent state-of-the-art review synthesizes current understanding of Btk's mechanistic contributions to thrombosis and CVD, evaluates the evolution of BTKi, and explores their therapeutic potential.
Autor:innen und Institutionen
- Ludwig Maximillians University Munich, Institute for Cardiovascular Prevention, Bavaria, Germany, Munchen.
- German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Bavaria, Germany, Munich.
- Munich Cluster for Systems Neurology (SyNergy), Bavaria, Germany, Munich.
- Maastricht University, Cardiovascular Research Institute Maastricht (CARIM), Department of Biochemistry, Limburg, The Netherlands, Maastricht.
ORCID-Profile: Philipp von Hundelshausen
Förderung
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
Zitieren
APA
von Hundelshausen, P., Siess, W., & Weber, C. (2026). Bruton Tyrosine Kinase as Therapeutic Target in Cardiovascular Diseases—Executive Summary. Thrombosis and Haemostasis. https://doi.org/10.1055/a-2886-8670
Vancouver
von Hundelshausen P, Siess W, Weber C. Bruton Tyrosine Kinase as Therapeutic Target in Cardiovascular Diseases—Executive Summary. Thrombosis and Haemostasis. 2026. doi:10.1055/a-2886-8670
BibTeX
@article{vonHundelshausen2026,
author = {von Hundelshausen, Philipp and Siess, Wolfgang and Weber, Christian},
title = {Bruton Tyrosine Kinase as Therapeutic Target in Cardiovascular Diseases—Executive Summary},
journal = {Thrombosis and Haemostasis},
year = {2026},
doi = {10.1055/a-2886-8670}
}
EUVIMED